Photodynamic therapy (PDT) has been demonstrated to be an effective tool for cancer treatment. Seeking organelle-targeting photosensitizers (PSs) with robust reactive oxygen species (ROS) production is extremely in demand. Herein, we propose an aggregation-induced photosensitization strategy for effective PDT with osmium complexes. We designed and synthesized three osmium complexes (, , and ) with ligands of different alkyl chains. In phosphate-buffered saline solution, the complex formed a spherical aggregate with diameters of around 220 nm. The results from ROS assays indicate that showed the highest efficiency in generating superoxide anions and singlet oxygen, demonstrating its role as a type I/II photosensitizer. Additionally, specifically targeted lysosomes in 4T1 and MCF-7 cells, producing ROS in a sustained and efficient manner with high phototoxicity (IC = 6.999 μM in MCF-7 cells), thereby inducing cancer cell death. In 4T1-tumor-bearing mice models, effectively inhibited tumor growth with a minimal impact on normal organs.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsabm.5c00224DOI Listing

Publication Analysis

Top Keywords

osmium complexes
12
aggregation-induced photosensitization
8
photodynamic therapy
8
mcf-7 cells
8
photosensitization long-chain-substituted
4
long-chain-substituted osmium
4
complexes lysosomes
4
lysosomes targeting
4
targeting photodynamic
4
therapy photodynamic
4

Similar Publications

Photodynamic therapy (PDT) has been demonstrated to be an effective tool for cancer treatment. Seeking organelle-targeting photosensitizers (PSs) with robust reactive oxygen species (ROS) production is extremely in demand. Herein, we propose an aggregation-induced photosensitization strategy for effective PDT with osmium complexes.

View Article and Find Full Text PDF

Proton-coupled electron transfer (PCET) underpins energy conversion processes in biological systems and fuel-forming reactions. Interrogation of the dynamics of electron and proton transfer in PCET processes requires tunable models, with synthetic transition metal aquo complexes being particularly well-explored examples. A previous study on a PCET model, [Os(bpy)(py)(OH)] (bpy = 2,2'-bipyridine; py = pyridine), reported synthetic intractability which limits access to this class of models.

View Article and Find Full Text PDF

Low-temperature protonation of the osmium(II) alkyl compounds (CMe)Os(dfmpm)R, where dfmpm = (FC)PCHP(CF) and R = ethyl, -propyl, -butyl, or -butyl, generates σ-ethane, σ-propane, σ--butane, and σ--butane complexes. The alkane dissociation barriers are ∼13.2 kcal mol or about 0.

View Article and Find Full Text PDF

Herein, the effects of a novel half-sandwich Os(II) complex on the aggregation of an amyloid model system, derived from the C-terminal domain of the nucleophosmin 1 protein (NPM1), were investigated. The thioflavin T (ThT) binding assay revealed that the complex [(η-toluene)Os(NHCglu)Cl] (where NHCglu is the N-heterocyclic carbene ligand 1-methyl-3-{2,3,4,6-tetra--acetyl-1-glucosyl}imidazol-2-ylidene), hence named , was able to repress amyloid aggregation in a dose-dependent way. Conformational studies through circular dichroism (CD) and Fourier transform infrared (FTIR) spectroscopies clearly indicated that this inhibitory effect occurred through the stabilization of α-helical structures of monomeric NPM1, thus hampering self-recognition.

View Article and Find Full Text PDF

Osmium complexes with osmium in different oxidation states (II, III, IV, and VI) have been reported to exhibit antiproliferative activity in cancer cell lines. Herein, we demonstrate unexplored opportunities offered by Os nuclear forward scattering (NFS) and nuclear inelastic scattering (NIS) of synchrotron radiation for characterization of hyperfine interactions and lattice dynamics in a benchmark Os(VI) complex, K[OsO(OH)]. We determined the isomer shift [δ = 3.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!